Trevi Therapeutics (TRVI) Net Cash Flow (QoQ) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101.31% |
| Dec 31, 2025 | 36.94% |
| Sep 30, 2025 | -161.62% |
| Jun 30, 2025 | 763.48% |
| Mar 31, 2025 | -181.59% |
| Dec 31, 2024 | 484.17% |
| Sep 30, 2024 | 464.27% |
| Jun 30, 2024 | 95.44% |
| Mar 31, 2024 | -388.96% |
| Dec 31, 2023 | -47.33% |
| Sep 30, 2023 | 481.29% |
| Jun 30, 2023 | 323.99% |
| Mar 31, 2023 | 98.26% |
| Dec 31, 2022 | -228.92% |
| Sep 30, 2022 | -15.92% |
| Jun 30, 2022 | 745.35% |
| Mar 31, 2022 | -202.73% |
| Dec 31, 2021 | 205.70% |
| Sep 30, 2021 | -38.13% |
| Jun 30, 2021 | -49.96% |
| Mar 31, 2021 | 58.62% |
| Dec 31, 2020 | -190.99% |
| Sep 30, 2020 | 208.03% |
| Jun 30, 2020 | -80.53% |
| Mar 31, 2020 | 24.65% |
| Dec 31, 2019 | 21.21% |
| Sep 30, 2019 | -113.47% |
| Jun 30, 2019 | 917.43% |
| Mar 31, 2019 | 190.71% |
| Dec 31, 2018 | -197.78% |
| Sep 30, 2018 | 172.76% |
| Jun 30, 2018 | -46.86% |